Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10031054 | 0.96 | LMNA (0.39) | EPHX2F2MEN1KMT2ACNR1 | |
| SCHEMBL10031069 | 0.92 | CNR1 (0.38) | EPHX2F2CNR1CNR2MAPT | |
| SCHEMBL13191345 | 0.91 | F2 (0.37) | F2MAPTBRD4HDAC3HDAC1 | |
| SCHEMBL10064727 | 0.91 | EPHX2 (0.44) | EPHX2F2CNR1CNR2MAPT | |
| SCHEMBL10064393 | 0.90 | F2 (0.36) | F2MAPTBRD4 | |
| SCHEMBL10031049 | 0.88 | LMNA (0.37) | F2CNR1CNR2MAPTBRD4 | |
| SCHEMBL13191317 | 0.85 | CNR1 (0.35) | F2CNR1CNR2MAPTBRD4 | |
| SCHEMBL10064294 | 0.85 | HTT (0.38) | MEN1KMT2ACNR1CNR2BRD4 | |
| SCHEMBL10031065 | 0.84 | MAPT (0.35) | F2CNR1CNR2MAPTBRD4 | |
| SCHEMBL13191324 | 0.82 | F2 (0.40) | EPHX2F2CNR1CNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077863-A1 | GUANIDINO-SUBSTITUTED BI-AND POLYPHENYLS AS SMALL MOLECULE CARRIERS | UCL BUSINESS PLC (GB) | 2012-03-29 | — | — | US | disclosed |
| WO-2010097604-A2 | NEW COMPOUNDS | UCL BUSINESS PLC (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077863-A1 | GUANIDINO-SUBSTITUTED BI-AND POLYPHENYLS AS SMALL MOLECULE CARRIERS | CFTR, GNB1, GMPS | EPHX2 1931/4885F2 794/4885MEN1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.